Farnesyl Thiosalicylic Acid Amide

Farnesyl Thiosalicylic Acid Amide (CAS 1092521-74-8)

Farnesyl Thiosalicylic Acid Amide | CAS 1092521-74-8 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_14, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_223986, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 98ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: FTS Amide; Salirasib Amide; 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-benzamide
Application: A Ras-mediated signaling inhibitor
CAS Number: 1092521-74-8
Purity: ≥96%
Molecular Weight: 357.6
Molecular Formula: C22H31NOS
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Farnesyl Thiosalicylic Acid Amide, association of Ras protein to the inner surface of the plasma membrane is required for Ras signaling activity. Farnesyl thiosalicylic acid (FTS) inhibits Ras-mediated signaling by dislodging Ras from the cell membrane thereby rendering it susceptible to proteolytic degradation. FTS amide is an FTS derivative with an amide added to the carboxyl group. FTS amide inhibits the growth of U87 and Panc-1 tumor cells with IC50values of 10 and 20 μM, respectively, a relatively higher potency compared to that of FTS (IC50s = 50 and 35 μM, respectively). Treatment of nude mice bearing either Panc-1 or U87 glioblastoma tumors with 100 mg/kg FTS-amide twice daily for four days inhibits tumor growth by at least 50% of controls.


References

1 Haklai, R., Weisz, M.G., Elad, G., et al. Dislodgment and accelerated degradation of ras. Biochemistry 37 1306-1314 (1998). 2 Goldberg, L., Haklai, R., Bauer, V., et al. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: Farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem 52 197-205 (2009).

Formulation :
A solution in ethanol
Physical State :
Liquid
Solubility :
Soluble in DMSO (~10 mg/ml), and DMF (~10 mg/ml).
Storage :
Store at -20° C
Boiling Point :
78° C
Refractive Index :
n20D 1.56 (Predicted)
IC50 :
Growth of U87 tumor cells: IC50 = 10 µM; Growth of Panc-1 tumor cells: IC50 = 20 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Transport :
UN 1170, Class 3, Packing group II
PubChem CID :
25187973
MDL Number :
MFCD11976913
SMILES :
CC(=CCC/C(=C/CC/C(=C/CSC1=CC=CC=C1C(=O)N)/C)/C)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 65ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from A decrease in p53 expression was observed A decrease in p53 expression was observed by WB in SW480 cells after treatment with Farnesyl Thiosalicylic Acid Amide. -SCBT QC
Date published: 2015-01-31
  • y_2019, m_11, d_14, h_14
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.2
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_223986, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 41ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.